All News
ILD in RA and PsA
Interstitial lung disease (ILD) is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.
Read Article
The thing that can influence bDMARD choice in PsA are the extra-MSK manifestations
“A little bit of a paradigm shift here” - Laure Gossec
2023 @eular_org recommendations
#EULAR2023 @RheumNow https://t.co/gr9IOg1bbj
David Liew drdavidliew ( View Tweet)
Which bDMARD first in PsA?
2023 @eular_org recommendation: no preferred order. All are equal in its eyes
#EULAR2023 @RheumNow https://t.co/6HNNamAj1J
David Liew drdavidliew ( View Tweet)
PsA recommendations update at #EULAR2023
New overarching principles - should take account of safety
@rheumnow https://t.co/rrZ0ViFRPs
Bella Mehta bella_mehta ( View Tweet)
Here are the PsA drugs that have come to market in recent years
(and what a few years it’s been)
#EULAR2023 @RheumNow https://t.co/asFsHAD21y
David Liew drdavidliew ( View Tweet)
PsA update at #EULAR2023 new mechanisms of actions since the 2019 guidelines @RheumNow https://t.co/zaieEHN6sW
Bella Mehta bella_mehta ( View Tweet)
ILD in RA and PsA
@AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD.
ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.
https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N
Links:
Dr. John Cush RheumNow ( View Tweet)
Metabolic Burden in the Early Stages of PsA
Dr. Aurelie Najm ( @AurelieRheumo )discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy.
https://t.co/Z39ibke3JD https://t.co/YvWbNz9tFH
Links:
Dr. John Cush RheumNow ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush RheumNow ( View Tweet)
Let le introduce you to ARTHUR 🤖
A very skilled robot who scans your hands and wrists in 15 mn 🤚
Amazing to see new #AI developments that will make our lifes’ easier!
#EULAR23 @ROPCA3 @JustSoren Stand M6
@RheumNow https://t.co/7PtR2CGqTt
Aurelie Najm AurelieRheumo ( View Tweet)
We need to assess CV risk in IA but how?
Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO
Bummer: these 3 prediction tools are less accurate in IA but also OA.
We need a dedicated tool.
@Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe
Aurelie Najm AurelieRheumo ( View Tweet)
A model predicts development of PsA in PSO cohort at 1 yr w/ AUC 72.3
Risk factors:
✔️younger age
✔️male
✔️family hx of PSO
✔️back stiffness
✔️nail pitting,
✔️stiffness
✔️PGA
✔️bioDMARDs
5yr prediction model AUC 75
Promising but to be confirmed
@RheumNow #EULAR23 POS0019 https://t.co/boCYOH2sDS
Aurelie Najm AurelieRheumo ( View Tweet)
Can combined US examination of nail-enthesis complex & nailfold videocapillaroscopy differentiate PsA from PSO RA and HC?
Brief answer is no, but:
-PsA > tortuous capillaries vs. PSO & HC
-Abnormalities in PSO to be used as predictor of PsA?
TBC...
@RheumNow #EULAR23 POS0025 https://t.co/RNbpht8QGh
Aurelie Najm AurelieRheumo ( View Tweet)
Fluorescence optical imaging in early arthritis?
Nice images but not ready for clinics yet
Can not differentiate OA from RA & PsA
SLE/SSc associated arthritis display a specific pattern, but usually auto-antibody profiles help w/ diagnosis
OP0173 #EULAR23 @Rheunow https://t.co/bAMi9kDKS5
Aurelie Najm AurelieRheumo ( View Tweet)
Mild correlation between fine motor hand skills and synovitis score grey scale and PD
However no correlation w/ TJC68/SJC66 https://t.co/ryCs21KRcB
Aurelie Najm AurelieRheumo ( View Tweet)
Loss of grip strength in PsA is NOT correlated w/ clinical parameters but US features
US study of 100+ pts w/ Pso or PsA
Strong correlation grip strength & grey scale tenosynovitis score (digit 2) r=-0.6
https://t.co/qClfMrhqhI OP0069 #EULAR23 @Rheumnow
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
🚨EULAR PtC clinical & imaging features suspicious for progression to PsA
Main take home messages ⬇️⬇️
Obesity, Nail Disease, Extensive PsO, Arthralgia, US detected synovio-entheseal
involvement/abnormalities in US = risks factors of developing PsA in PsO pts.
@Rheumnow #EULAR23
Aurelie Najm AurelieRheumo ( View Tweet)
Provan et al. large scandinavian registry study: 🫁ILD risk in RA & PsA initiating b/tsDMARDs
HR ILD RA=10
HR ILD PsA=5
No increase risk w/ MTX and b/tsDMARDs but RA HR ILD 1.7 RTX vs. ETA: confounding by indication?
https://t.co/CF1ysNkQxU OP0006 #EULAR23 @Rheumnow https://t.co/DgDE1uFeUs
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Data from combined big Scandinavian population registries looking at both RA and PsA, ILD development, & MTX exposure
Here’s the ILD risk for methotrexate.
Can we stop this MTX misinformation? No more besmirching a really useful drug for our patients #EULAR2023 OP0006 @RheumNow https://t.co/7swqAYchDC
David Liew drdavidliew ( View Tweet)
Interstitial lung disease in RA and PSA in b/tsDMARD treated patients with MTX - there is no increased risk of developing ILD above the background risk of RA and PsA vs general population Sella Aarrestad Provan Abst#OP0006 @RheumNow https://t.co/yJsrmraeZ5
Dr. Antoni Chan synovialjoints ( View Tweet)
